Find Funding Opportunities

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Expiration Date: Saturday, May 8, 2027 NOFO Number: PA-24-184 Release Date: Tuesday, April 9, 2024 Notice Type: PA
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
Expiration Date: Saturday, October 5, 2024 NOFO Number: PAR-24-196 Release Date: Friday, April 5, 2024 Notice Type: PAR
(Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia.
Expiration Date: Tuesday, July 23, 2024 NOFO Number: RFA-TR-24-021 Release Date: Friday, April 5, 2024 Notice Type: RFA
This is a non-competitive funding opportunity intended to fund a single award. NCATS is announcing its intent to issue a single source cooperative agreement to Cincinnati Childrens Hospital Medical Center (CCHMC) to support the Data Management and Coordinating Center. The Rare Diseases Clinical Research Network (RDCRN) is intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research with an emphasis on early and timely identification of individuals with rare diseases and clinical trial readiness. The DMCC facilitates and supports the activities of each individual Rare Diseases Clinical Research Consortium (RDCRC) along with trans-network activities that broadly facilitate the advancement of rare disease research via four avenues: administrative support, data management support, clinical research support and patient engagement, and broad dissemination of information. The RDCRCs will continue conducting research conducted under a separate NOFO.
Expiration Date: Wednesday, July 31, 2024 NOFO Number: RFA-HD-25-001 Release Date: Wednesday, April 3, 2024 Notice Type: RFA
This Notice of Funding Opportunity (NOFO) invites grant applications from institutions/organizations that propose to build a Medical Rehabilitation Research Center. The centers will have a specific rehabilitation research theme and be comprised of a research project supported by 3 cores. The 3 cores will have functions within the center as well as functions nationwide. Together, the cores will support: administrative functions (including an optional pilot program), resource sharing, and community engagement and outreach. The Medical Rehabilitation Research Centers will contribute tomedical rehabilitation research infrastructure by developing and disseminating techniques, data, theories, research programs, and expertise with the goal of enhancing the capability of medical rehabilitation investigators to understand mechanisms of functional recovery, develop therapeutic strategies, identify clinical care gaps, and improve the lives of people with disabilities. Applications must include a plan for inclusion of People with Lived Experience (as a required other attachment) that is relevant to the research theme of the center and increases the potential impact of the center.
Expiration Date: Wednesday, August 14, 2024 NOFO Number: PAR-24-206 Release Date: Tuesday, April 2, 2024 Notice Type: PAR
The objective of this Notice of Funding Opportunity (NOFO) is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness.
Expiration Date: Friday, June 19, 2026 NOFO Number: NOT-OD-24-078 Release Date: Wednesday, March 27, 2024 Notice Type: Notice of Special Interest
This notice announces the availability of funds from the Office of Data Science Strategy (ODSS) to NIH-managed or NIH-majority-funded projects that may benefit from using the cloud. The purpose of this announcement is to explore and test potential opportunities for leveraging cloud solutions to enhance existing NIH activities. Projects already using cloud may apply to explore and test cloud capabilities not yet leveraged. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at building a better data infrastructure and a modernized data ecosystem.
Expiration Date: Wednesday, January 8, 2025 NOFO Number: PAR-24-169 Release Date: Wednesday, March 27, 2024 Notice Type: PAR
This notice of opportunity announcement (NOFO) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.
Research Category: HEAL Initiative, Pain Expiration Date: Saturday, January 16, 2027 NOFO Number: RFA-NS-25-012 Release Date: Tuesday, March 26, 2024 Notice Type: RFA

This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program. The scope will therefore be focused on development of assays to support a distinct testing funnel, screening efforts to identify hits, and initial characterization of hits and potential therapeutic agents (including small molecules, biologics, and natural products).

Expiration Date: Friday, November 5, 2027 NOFO Number: NOT-OD-24-079 Release Date: Tuesday, March 26, 2024 Notice Type: Notice of Special Interest
In alignment with the White House Initiative on Womens Health Research, the National Institutes of Health (NIH) is issuing this Notice of Special Interest to highlight interest in receiving research applications focused on diseases and health conditions that predominantly affect women (e.g., autoimmune diseases; depressive disorders, Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or are female-specific (e.g., uterine fibroids; endometriosis; menopause).
Expiration Date: Friday, January 29, 2027 NOFO Number: RFA-NS-24-016 Release Date: Wednesday, March 20, 2024 Notice Type: RFA
Reissue: RFA-NS-21-023 - The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.
Export to:
A maximum of 400 records can be exported.